Pharmacological Treatments against COVID-19 in Pregnant Women

The recent respiratory virus known as SARS-CoV-2 has caused millions of deaths worldwide, causing great uncertainty due to the lack of a specific treatment, which has been mitigated by the use of various drugs traditionally used against other types of pathologies. Pregnancy presents special physiolo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ana Arco-Torres, Jonathan Cortés-Martín, María Isabel Tovar-Gálvez, María Montiel-Troya, Blanca Riquelme-Gallego, Raquel Rodríguez-Blanque
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 COVID-19 virus pregnant woman foetus pharmacological treatment Medicine R
Acceso en línea:	https://doaj.org/article/27e679a1e9484b3f84a849e6ec623d02
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:27e679a1e9484b3f84a849e6ec623d02
record_format	dspace
spelling	oai:doaj.org-article:27e679a1e9484b3f84a849e6ec623d022021-11-11T17:32:48ZPharmacological Treatments against COVID-19 in Pregnant Women10.3390/jcm102148962077-0383https://doaj.org/article/27e679a1e9484b3f84a849e6ec623d022021-10-01T00:00:00Zhttps://www.mdpi.com/2077-0383/10/21/4896https://doaj.org/toc/2077-0383The recent respiratory virus known as SARS-CoV-2 has caused millions of deaths worldwide, causing great uncertainty due to the lack of a specific treatment, which has been mitigated by the use of various drugs traditionally used against other types of pathologies. Pregnancy presents special physiological conditions that expose the pregnant woman and the foetus to greater risk. Pregnant women are often excluded from trials due to possible risk of toxicity or side effects, resulting in a lack of knowledge about the use of drugs and treatments during pregnancy. The main objective of this review was to compile existing knowledge about currently available drug treatments for COVID-19 in pregnant women. The review report met the criteria of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) review protocol and was registered with the registration number CRD42021251036. The electronic databases searched were Scopus, PubMed, CINAHL and SciELO. Finally, 22 articles were included, resulting in an analysis of drugs with an acceptable safety profile in the treatment of pregnant women with COVID-19.Ana Arco-TorresJonathan Cortés-MartínMaría Isabel Tovar-GálvezMaría Montiel-TroyaBlanca Riquelme-GallegoRaquel Rodríguez-BlanqueMDPI AGarticleSARS-CoV-2COVID-19viruspregnant womanfoetuspharmacological treatmentMedicineRENJournal of Clinical Medicine, Vol 10, Iss 4896, p 4896 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 COVID-19 virus pregnant woman foetus pharmacological treatment Medicine R
spellingShingle	SARS-CoV-2 COVID-19 virus pregnant woman foetus pharmacological treatment Medicine R Ana Arco-Torres Jonathan Cortés-Martín María Isabel Tovar-Gálvez María Montiel-Troya Blanca Riquelme-Gallego Raquel Rodríguez-Blanque Pharmacological Treatments against COVID-19 in Pregnant Women
description	The recent respiratory virus known as SARS-CoV-2 has caused millions of deaths worldwide, causing great uncertainty due to the lack of a specific treatment, which has been mitigated by the use of various drugs traditionally used against other types of pathologies. Pregnancy presents special physiological conditions that expose the pregnant woman and the foetus to greater risk. Pregnant women are often excluded from trials due to possible risk of toxicity or side effects, resulting in a lack of knowledge about the use of drugs and treatments during pregnancy. The main objective of this review was to compile existing knowledge about currently available drug treatments for COVID-19 in pregnant women. The review report met the criteria of the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) review protocol and was registered with the registration number CRD42021251036. The electronic databases searched were Scopus, PubMed, CINAHL and SciELO. Finally, 22 articles were included, resulting in an analysis of drugs with an acceptable safety profile in the treatment of pregnant women with COVID-19.
format	article
author	Ana Arco-Torres Jonathan Cortés-Martín María Isabel Tovar-Gálvez María Montiel-Troya Blanca Riquelme-Gallego Raquel Rodríguez-Blanque
author_facet	Ana Arco-Torres Jonathan Cortés-Martín María Isabel Tovar-Gálvez María Montiel-Troya Blanca Riquelme-Gallego Raquel Rodríguez-Blanque
author_sort	Ana Arco-Torres
title	Pharmacological Treatments against COVID-19 in Pregnant Women
title_short	Pharmacological Treatments against COVID-19 in Pregnant Women
title_full	Pharmacological Treatments against COVID-19 in Pregnant Women
title_fullStr	Pharmacological Treatments against COVID-19 in Pregnant Women
title_full_unstemmed	Pharmacological Treatments against COVID-19 in Pregnant Women
title_sort	pharmacological treatments against covid-19 in pregnant women
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/27e679a1e9484b3f84a849e6ec623d02
work_keys_str_mv	AT anaarcotorres pharmacologicaltreatmentsagainstcovid19inpregnantwomen AT jonathancortesmartin pharmacologicaltreatmentsagainstcovid19inpregnantwomen AT mariaisabeltovargalvez pharmacologicaltreatmentsagainstcovid19inpregnantwomen AT mariamontieltroya pharmacologicaltreatmentsagainstcovid19inpregnantwomen AT blancariquelmegallego pharmacologicaltreatmentsagainstcovid19inpregnantwomen AT raquelrodriguezblanque pharmacologicaltreatmentsagainstcovid19inpregnantwomen
_version_	1718432051564118016

Pharmacological Treatments against COVID-19 in Pregnant Women

Ejemplares similares